Concor Cor, pills 2.5mg 30pcs

Composition

Coated tablets. 1 table. contains bisoprolol fumarate 2.5 mg; other ingredients: colloidal silicon dioxide, magnesium stearate, crospovidone, microcrystalline cellulose, corn starch, calcium hydrophosphate, dimethicone 100, macrogol 400, iron oxide, titanium oxide, methylhydroxypropylcellulose.

Pharmacological action

Concor Core is a selective beta-1-adrenoblocker. When used in therapeutic doses, it does not have internal sympathomimetic activity and clinically significant membrane-stabilizing properties. After oral use, the effect develops in 1-3 hours and lasts for 24 hours. It has a hypotensive effect by reducing cardiac output, inhibiting renin secretion by the kidneys, and acting on the baroreceptors of the aortic arch and carotid sinus. With prolonged use of Concor, Kor reduces the initially increased OPSS. It has an antianginal effect. Reduces myocardial oxygen demand by reducing heart rate, reducing cardiac output, and lowering blood pressure. Increases the supply of oxygen to the myocardium by reducing the final diastolic pressure and lengthening the diastole. In chronic heart failure, Concor Core suppresses the activated sympatho-adrenal and renin-angiotensin-aldosterone systems, which leads to an improvement in the course of the disease.

Indications

-arterial hypertension– – IHD (angina pectoris);– chronic heart failure.

Use during pregnancy and lactation

Concor should not be prescribed during pregnancy and lactation (breastfeeding) due to the lack of clinical experience in using the drug in this category of patients. In exceptional cases of Concor use during pregnancy, MI treatment should be discontinued 72 hours before the expected delivery date due to the possibility of bradycardia, hypoglycemia and respiratory depression of the newborn. If withdrawal of the drug is not possible, then after delivery, the newborn should be carefully monitored. Symptoms of hypoglycemia can be expected within the first 3 days.

Contraindications

– shock; – AV blockade II and III degree;– SSSU;– severe sinoatrial block;– a tendency to bronchospasm (bronchial asthma, obstructive Airways disease);– late stages of peripheral circulatory disorders;– simultaneous reception of MAO inhibitors (except MAO inhibitors type);– when specifying a history from the patient or his relatives psoriasis (the use of beta-blockers, including Concor Cor, should be done only after careful evaluation of the balance of risks and benefits;– pheochromocytoma (appointment of Concor Cor in patients with pheochromocytoma is allowed only after taking alpha-blockers);– in patients with chronic heart failure Concor Cor should not be used during exacerbation of heart failure or during episodes of heart failure decompensation requiring I/introduction of drugs affecting myocardial contractility;in addition, for patients with chronic heart failure is contraindicated the use of Concor Cor with bradycardia if the pulse is less than 50-60/min and hypotension if the systolic blood pressure less than 90 to 100 mm Hg. article

Side effects

From the central nervous system and peripheral nervous system: fatigue, dizziness, headache, sleep disturbance, depression are possible (especially at the beginning of the course of treatment); rarely – hallucinations. Usually, these phenomena are mild and usually disappear within 1-2 weeks. From the side of the organ of vision: rarely-visual impairment, reduced tear production (should be taken into account when wearing contact lenses), conjunctivitis. From the cardiovascular system: in some cases – orthostatic hypotension, bradycardia, violation of AV conduction, decompensation of heart failure with the development of peripheral edema; paresthesia and a feeling of cold in the extremities are possible. At the beginning of treatment, the condition may worsen in patients with intermittent claudication or with Raynaud’s syndrome. From the respiratory system: rarely-shortness of breath (in patients with a tendency to bronchospasm, including bronchitis with bronchoobstructive syndrome). From the digestive system: in some cases-diarrhea, constipation, nausea, abdominal pain, increased activity of liver enzymes in blood plasma (AST, ALT), hepatitis. From the musculoskeletal system: in some cases – muscle weakness, muscle cramps, arthropathy with damage to one or more joints (mono – or polyarthritis). From the endocrine system: reduced glucose tolerance (in latent diabetes mellitus) and masked signs of hypoglycemia; in some cases, an increase in blood triglycerides. On the part of the reproductive system: in some cases – a violation of potency. Dermatological reactions: itching is possible; rarely-redness of the skin, increased sweating, rash.

Interaction

Concor may increase the effect of antihypertensive drugs when used concomitantly. Concor and reserpine, alpha-methyldopa, clonidine, digitalis preparations or guanfacine may cause a sharp decrease in heart rate. With the simultaneous use of Concor and clonidine, digitalis preparations, as well as guanfacine, conduction disturbances are also possible. Concor and sympathomimetics (including those contained in cough suppressants, nasal drops and eye drops) may reduce the effect of bisoprolol. Concomitant use of nifedipine and other calcium channel blockers – dihydropyridine derivatives-may enhance the antihypertensive effect of Concor. Concor and verapamil, or diltiazem and other antiarrhythmic drugs may cause a sharp decrease in blood pressure, a decrease in heart rate, and the development of arrhythmia and/or heart failure (careful medical supervision is required). Calcium channel blockers and antiarrhythmic drugs should not be administered intravenously during Concor therapy. When Concor and clonidine are used simultaneously, the latter can only be discontinued if Concor has been discontinued several days before, due to the risk of an excessive increase in blood pressure. Concomitant use of ergotamine derivatives (including ergotamine-containing drugs for the treatment of migraines) and Concor may increase peripheral circulatory disorders. Concor and rifampicin concomitantly may cause a slight decrease in T1 / 2 bisoprolol (an increase in the Concor dose is usually not required). Concomitant use of Concor and insulin or oral hypoglycemic agents may increase the hypoglycemic effect. Symptoms of hypoglycemia are masked or mitigated (regular monitoring of blood glucose levels is necessary).

How to take, course of use and dosage

The following dosage regimen is recommended: the initial dose of Concor Core is 1.25 mg 1 time / day for the first week. During the second week of use,2.5 mg/day is prescribed. In the third week of treatment, the dose is 3.75 mg / day. From the fourth to the eighth week of admission,5 mg is prescribed (2 tablets). Concor Core or 1 tab. of Concor preparation containing 5 mg bisoprolol fumarate or 1/4 tab. Concorde containing 10 mg of bisoprolol fumarate). Then the dose is increased to 7.5 mg (from the eighth to the twelfth week). After the twelfth week of treatment, the maximum dose is prescribed-10 mg (4 tablets of Concor Kor or 2 tablets of Concor Kor). Concorde containing 5 mg bisoprolol fumarate or 1 tab. Concorde containing 10 mg of bisoprolol fumarate). The doctor may adjust the dosage regimen depending on individual tolerance. After starting treatment with Concor Kor at a dose of 1.25 mg, a patient with chronic heart failure should be examined for 4 hours (blood pressure, heart rate, conduction disturbances, worsening of heart failure symptoms). The appearance of side effects may prevent patients from prescribing the maximum recommended dose. If necessary, the achieved dose can be gradually reduced. Treatment can be stopped if necessary, and then resumed according to the same scheme. If intolerance develops or symptoms of heart failure worsen during the dose increase process, it is recommended to first reduce the dose of Concor Kor or stop taking the drug (in case of severe hypotension, worsening of heart failure symptoms accompanied by acute pulmonary edema, cardiogenic shock, bradycardia or AV block). Tablets should be taken without chewing, washed down with a small amount of liquid. It is recommended to take Concor Cor in the morning on an empty stomach or during breakfast. During treatment, regular monitoring of the doctor is required. The course of treatment with Concor Kor is usually long. The patient should not change the dose or discontinue treatment without instructions from the attending physician. Avoid sudden discontinuation of Concor Kor treatment. The course of treatment should be completed by gradually reducing the dose. This is especially important in the treatment of patients with coronary artery disease, as well as with chronic heart failure (in such cases, the dose should be reduced 2 times weekly). In all cases, the duration of treatment with the drug is determined by the doctor.

Overdose

Symptoms: bradycardia, hypotension, heart failure, bronchospasm. Treatment: gastric lavage, taking activated charcoal. With bradycardia or arterial hypotension, intravenous use of atropine in a dose of 1.5 to 2 mg, use of glucagon in a dose of 1-5 mg (up to 10 mg) is possible. For bronchospasm, beta-2-adrenomimetics are used (for example, salbutamol or fenoterol).

Special instructions

Caution should be exercised when treating patients with diabetes mellitus with significant fluctuations in blood glucose, assymptoms of hypoglycemia can be masked; in the treatment of patients who adhere to a strict diet; in the treatment of patients with metabolic acidosis; in patients with a history of severe hypersensitivity reaction; in desensitizing therapy; in AV blockade of the first degree; in angiospastic angina pectoris (Prinzmetal angina pectoris). In some cases, the use of beta-blockers (including Concor) can cause the development or worsening of the course of psoriasis or lead to the appearance of psoriatic rashes on the skin. Against the background of taking beta-blockers, more severe forms of hypersensitivity reactions may occur. When treated with beta-blockers, in some cases there is hair loss, hearing loss or tinnitus, weight gain, mood changes, short-term memory loss, allergic rhinitis. Before performing surgery, you should inform the anesthesiologist about taking Concor. Use in pediatrics Concor should be prescribed to children due to the lack of clinical experience with the drug in this category of patients. The question of the possibility of engaging in potentially dangerous activities that require increased attention and speed of psychomotor reactions should be resolved only after evaluating the individual patient’s response to the drug (especially at the beginning of treatment or with simultaneous use of alcohol or ethanol-containing drugs).

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years

Active ingredient

Bisoprolol

Conditions of release from pharmacies

By prescription

Dosage form

Tablets